Skip to main content
    F

    Fennec Pharmaceuticals Inc (FENC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.58
    +0.82 (+6.43%)

    Market Cap: $410.25M

    Last updated: Nov 17, 2026 at 4:42 PM ET

    Fennec Pharmaceuticals Inc (FENC) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Fennec Pharmaceuticals (FENC) has a market cap of $410.25M and an enterprise value of $361.56M. Its share count is up 25.90% from a year earlier. Revenue grew 71.09% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 11.87% below the market cap, as cash exceeds debt.

    Market Cap$410.25M
    Enterprise Value$361.56M
    Latest price (Nov 17, 2026)$13.58

    Key Dates

    The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 22, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.64% in the quarter ended Sep 30, 2026 and grew 13.26% a year over 2 years.

    Shares Outstanding35.11M
    Shares Change (YoY)+25.90%
    Shares Change (QoQ)+1.64%
    Share Count Growth (2Y CAGR)+13.26%

    Valuation Ratios

    Sales and book value multiples are 7.2x and 9.7x.

    P/E Ratio169.8x
    Forward P/E47.0x
    P/S Ratio7.2x
    Forward P/S5.5x
    P/B Ratio9.7x
    P/OCF Ratio130.3x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 109.5x EBITDA.

    EV / Earnings178.3x
    EV / Sales5.4x
    EV / EBITDA109.5x
    EV / EBIT97.7x

    Price Statistics

    The stock is up 72.77% over 52 weeks and trades 27.27% above its 50-day average.

    Beta (1Y)1.41
    52-Week Change+72.77%
    1-Month Change+32.23%
    3-Month Change+14.41%
    6-Month Change+39.14%
    5-Year Change+10.58%
    10-Year Change+409.45%
    Total Return (1Y)+72.77%
    Total Return (3Y CAGR)+17.74%
    Total Return (5Y CAGR)+6.64%
    Return vs SPY (1Y)+43.64%
    Max Drawdown (1Y)-35.82%
    Max Drawdown (3Y)-65.63%
    Sharpe Ratio (1Y)0.67
    Correlation with SPY (1Y)0.30
    50-Day Average$10.67
    200-Day Average$9.41
    52-Week Range$5.65 to $13.25
    RSI (14 Days)72.8
    Average Volume (20 Days)247.82K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.11x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio6.11x
    Quick Ratio5.95x
    Debt / Equity0.00x
    Interest Coverage1.56x

    Returns and Efficiency

    Return on equity is 4.12% and return on assets is 2.43% over the last 12 months.

    Return on Equity (ROE)4.12%
    Return on Assets (ROA)2.43%
    Return on Capital Employed (ROCE)5.27%
    ROA (5Y Average)-47.98%
    ROIC (5Y Average)110.03%
    Asset Turnover1.00x
    Inventory Turnover1.73x
    Receivables Turnover2.82x
    Cash Conversion Cycle-135 days

    Taxes

    Income tax took 16.21% of pretax income over the last 12 months.

    Income Tax (TTM)$374.00K
    Effective Tax Rate16.21%

    Scores

    FENC has an Altman Z-Score of 6.51, in the safe zone above 2.99, and a Piotroski F-Score of 0 of 9, in the weak band of 0 to 2.

    Altman Z-Score6.51
    Altman Z ZoneSafe
    Piotroski F-Score0 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $66.37M over the last 12 months.

    Revenue$66.37M
    Revenue Growth (YoY)+71.09%
    Gross Profit$62.47M
    Operating Income$3.72M
    Pretax Income$2.31M
    Net Income$2.03M
    EBITDA$3.91M
    EBIT$3.70M
    Reported EPS (TTM)$0.08

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 58.88% of the $83.54M in total assets.

    Cash and Equivalents$48.68M
    Total Debt$0
    Net Cash$48.68M
    Net Cash Per Share$1.39
    Working Capital$67.71M
    Shareholder Equity$49.19M
    Book Value Per Share$1.40
    Total Assets$83.54M
    Total Liabilities$34.35M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow$3.15M
    FCF Per Share$0.09
    Depreciation and Amortization$207.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 5.60%.

    Gross Margin94.13%
    Operating Margin5.60%
    Pretax Margin3.48%
    Net Margin3.06%
    EBITDA Margin5.89%
    EBIT Margin5.58%

    Growth

    Revenue grew 207.52% a year over 3 years.

    Revenue Growth (3Y CAGR)+207.52%
    Revenue Growth (5Y CAGR)+204.69%

    Revenue and profit by year

    Dividends and Yields

    FENC does not pay a dividend.

    Earnings Yield0.59%
    Shareholder Yield0.00%

    Peer Position

    Against 7 similar companies, FENC has the 4th highest P/S.

    P/S Ratio7.2x vs 4.3x median
    Revenue Growth (Trailing 4 Quarters, YoY)+71.09% vs -27.97% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 53.64% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+53.64%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About FENC

    What is FENC's market cap?

    Fennec Pharmaceuticals has a market cap of $410.25M. Its enterprise value, which adds debt and subtracts cash, is $361.56M.

    What is FENC's P/E ratio?

    Fennec Pharmaceuticals has a trailing P/E ratio of 169.8x and a forward P/E of 47.0x.

    How many shares of FENC are outstanding?

    Fennec Pharmaceuticals has 35.11M shares outstanding. The count is up 25.90% from a year earlier.

    Does FENC pay a dividend?

    No. Fennec Pharmaceuticals does not pay a dividend.

    How much debt does FENC have?

    Fennec Pharmaceuticals has $0 of total debt and $48.68M of cash and equivalents, a net cash position of $48.68M.